Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia

Valera, Elvis Terci; Scrideli, Carlos Alberto; Queiróz, Rosane Gomes de Paula; Mori, Bianca Maria; Tone, Luíz Gonzaga

doi:10.1590/s1516-31802004000400007

Cited by 50 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certain relationships, for instance, between CD10 and MRD1, 23 low WBC count and MRD1, 24 in addition to CD34 and MRP1, 25 have been noted in scientific literature; nonetheless, these reports are controversial and without consistency, and in many reports the expression of these genes was found to be unrelated to the mentioned risk factors. 12,13,22,[26][27][28] One major objective of this study was to determine whether or not the expression of genes studied may be used as an independent risk factor for drug resistance at the onset of therapy. As previously mentioned, the gene profile of newly diagnosed patients is not significantly different from that of healthy individuals, while the expression is different within patients with ALL.…”

Section: Discussionmentioning

confidence: 99%

mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2

Rahgozar

Moafi

Abedi

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2

Rahgozar

Moafi

Abedi

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Although the true clinical prevalence of MDR is difficult to assess as only a minority of cancer patients are tested for the MDR phenotype, MDR is implied in most cases of non-responsive recurrence and has been clearly associated with treatment failure in many different types of cancer in patients with diverse demographics [6][7][8][9][10][11][12][13][14][15][16][17]. MDR has been linked to poor prognosis and reduced survival in gastric cancer, gliomas, sarcomas, breast cancer, ovarian cancer, pancreatic cancer, and hematological malignancies, including childhood acute lymphoblastic leukemia and acute myeloid leukemia [6][7][8][9][10][11][12][13][14][15][16][17].…”

Section: Tumor Microenvironment and Mdrmentioning

confidence: 99%

“…MDR has been linked to poor prognosis and reduced survival in gastric cancer, gliomas, sarcomas, breast cancer, ovarian cancer, pancreatic cancer, and hematological malignancies, including childhood acute lymphoblastic leukemia and acute myeloid leukemia [6][7][8][9][10][11][12][13][14][15][16][17].…”

Section: Tumor Microenvironment and Mdrmentioning

confidence: 99%

Multi-functional nanocarriers to overcome tumor drug resistance

Jabr-Milane¹,

Vlerken²,

Yadav³

et al. 2008

Cancer Treatment Reviews

376

251

View full text Add to dashboard Cite

The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that lower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and light) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors.

show abstract

“…To our knowledge, this is the first investigation of the effect of the C3435T multiple drug resistance SNP in pediatric patients with ALL in Indonesia. Although chemotherapy arrests as much as 80% of childhood ALL, almost 25% of cured children will relapse [19].…”

Section: Discussionmentioning

confidence: 99%

Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

et al. 2015

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in the pediatric population. From 25% to 30% of patients with ALL will have a relapse that leads to death when they are teenagers. At Cipto Mangunkusumo Hospital, 40% of 126 pediatric patients with ALL relapsed from 2005 to 2011. A multiple variant of multidrug resistance gene 1 (MDR1) is C3435T, which can be used to understand the genetic basis of susceptibility to relapse. Objectives: To identify the profile of MDR1 polymorphism in pediatric Indonesian patients with ALL. Methods: We collected data from 44 patients with ALL who attended Cipto Mangunkusumo Hospital between January and June 2014. We investigated a silent C3435T polymorphism in MDR1 exon 26 with polymerase chain reaction-restriction fragment length polymorphism using MboI. Results: There were 32 male and 12 female patient participants in this study. Eighteen patients were 1−3 years old and 26 were over 3 years. The mean age at 1−3 years was 2.4 ± 0.86, and over 3 years it was 6.3 ± 2.67 years. There were 27 patients with ALL in the standard risk group and 17 in the high risk group. We determined that the 25 samples from patients with ALL in the standard risk group were not digestible (allele T) and the 6 samples from patients with ALL in the high risk group were digestible (allele C). Conclusions: The prevalence of the T allele was higher than that of the C allele in pediatric Indonesian patients with ALL.

show abstract

Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia

Abstract: Evaluation of the expression of genes for resistance to antineoplastic drugs in childhood acute lymphoblastic leukemia upon diagnosis, and particularly the expression of the LRP gene, may be of clinical relevance, and should be the object of prospective studies.

Cited by 50 publications

References 16 publications

mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2

mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2

Multi-functional nanocarriers to overcome tumor drug resistance

Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

Contact Info

Product

Resources

About